C91.62
Prolymphocytic leukemia of T-cell type, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Prolymphocytic leukemia of T-cell type is a rare form of blood cancer characterized by an abnormal increase of T-lymphocytes, a type of white blood cell essential for immune response. When this disease reappears after treatment, it is termed 'in relapse.' Relapse indicates that the cancer has returned and might require further medical intervention.
Causes & Symptoms
Clinical Causes: The exact cause of prolymphocytic leukemia remains unknown, but it involves genetic mutations within T-lymphocytes. Exposure to certain chemicals or radiation may increase risk, although specific links are not clearly established. Age is a significant factor, with the disease typically diagnosed in older adults. Family history of lymphoid cancers may contribute to risk, though cases are relatively sporadic.
Key Symptoms: Unintentional weight loss Persistent fatigue or weakness Swollen lymph nodes, especially in neck, armpits, or groin Fever and night sweats Frequent infections due to compromised immunity Enlarged spleen or liver causing abdominal discomfort Bruising or bleeding easily
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of blood tests, bone marrow biopsy, and imaging studies. Medical professionals examine blood smears to identify the presence of abnormal T-cells and assess the extent of disease. Flow cytometry helps differentiate the cancer type. Additional tests may include genetic studies to identify specific mutations associated with the disease.
Treatment Protocols: Treatment strategies for relapsed prolymphocytic leukemia of T-cell type are tailored to the individual and may include:
Clinical Advice & FAQs
Billing Guidance
Is C91.62 a billable ICD-10 code?
Yes, C91.62 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.62?
Clinical documentation must specify the nature of Prolymphocytic leukemia of T-cell type, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference